Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study

Abstract

Background: Little is known about the clinical features of breast cancer with synchronous hepatic metastases (BCSHM). In this retrospective study, we aimed to feature the incidence and survival outcome of BCSHM.Methods: Data from the 2016 SEER*Stat database (version 8.3.2) was used. The effect of patient and tumor characteristics on the odds of developing of BCSHM was analyzed. Survival was investigated using Kaplan-Meier and Cox regression analyses. A competing risk model was also applied to further investigate cancer-specific survival.Results: Of 240911 patients with breast cancer, we identified 3468 patients (1.44%) with BCSHM. Tumor subtypes distribution of BCSHM were 45.3% HR+/HER2-, 12.2% HR+/HER2+, 7.83% HR-/HER2+ and 15.0% triple-negative subtype. The median OS of the entire cohort was 14 months, and only about 13.5% of patients survived at 3 years. Median survival was significantly shorter in triple-negative cohort (8 months) and gradually increased in HR+/HER2- (19 months), HR-/HER2+ (22 months) and HR+/HER2+ (33 months) cohorts (P<0.05). Patients BCSHM were more likely to be young age (odds ratio [OR] 1.4, 95% CI 1.0-2.0), black race (OR 1.13, 95%CI 1.11-1.37), higher tumor grade (OR 3.58, 95%CI 2.29-5.59), unmarried status (OR 3.5, 95%CI 2.1-5.7), HR-/HER2+ (OR 4.07, 95%CI 3.56-4.67), HR+/HER2+ (OR 2.5, 95%CI 2.24-2.80) and triple-negative subtypes (OR 1.64, 95%CI 1.44-1.86). Poor prognostic factors were the aged (hazard ratio 3.75, 95%CI 3.56-4.67), black race (hazard ratio 1.17, 95%CI 1.03-1.31), triple-negative subtype (hazard ratio 2.23, 95%CI 1.95-2.56) and higher grade (hazard ratio 1.32, 95%CI 1.03-1.68).Conclusion: In conclusion, patients with BCSHM had a poor survival, and only 13.5% of them were alive more than 3 years. Young patients with HER2+ tumors had higher risk for developing BCSHM, but with better prognosis.

Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine

“…Because lung metastasis of breast cancer is responsible for a majority of treatment failures [ 64 , [69] , [70] , [71] ], the efficiency of preventing metastasis was also paid great attention. Therefore, we first assessed the direct impact of drug formulations on the metastatic potential of 4T1 cells in vitro .…”

Targeting Hypoxic Tumors with Hybrid Nanobullets for Oxygen-Independent Synergistic Photothermal and Thermodynamic Therapy

“…5 e and S21, both HA-ACVA-AZ NBs and ZPA@HA-ACVA-AZ NBs with AZ could inhibit the expression of CA IX slightly and ZPA@HA-ACVA-AZ NBs + laser induced a more significant decrease of CA IX expression (58.4%), suggesting that suppressing migration of hypoxic 4T1 cells was highly relevant to the down-regulating the expression of CA IX. For in vivo study, lung metastasis is commonly diagnosed at the later stage of breast cancer, which is closely relevant to death in breast cancer [ 49 – 51 ]. After the tumor inhibition experiment, the lung-metastasized foci in each group were counted (Fig.…”

Risk factors and survival outcomes of laryngeal squamous cell carcinoma patients with lung metastasis: A population-based study

“…Married patients may be more active in treating primary tumors, or spouses may urge patients to treat more actively, thus reducing the risk of LM. This also indicated that marital status may affect how cancer patients get access to health services and affect survival time of patients with cancer [17] .…”